Retinopathy of Prematurity

Volume 34, Number # 2, 2006 Series

1. Vyas J, Field D, Draper ES, et al.: Severe retinopathy of prematurity and its association with different rates of survival in infants less than 1251g birth weight.
Arch Dis Child Fetal Neonatal Ed 2000;82:F145-9.

2. Pennefather PM, Tin W, Clarke MP, et al. Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment. Br J Ophthalmol 1996;80:420-4.

3. Bullard SR, Donahue SP, Feman SS, et al. The decreasing incidence and severity of retinopathy of prematurity. J AAPOS 1999;3:46-52.

4. The Committee for the Classification of Retinopathy of Prematuriyu. An International classification of retinopathy of prematurity. Arch Ophthalmol 1984; 102:1130-1134.

5. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: 3�-year outcome � structure and function. Arch Ophthalmol 1993;111:339-44.

6. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP): Good WV, Hardy RJ. Ophthalmology 2001;108:1013-1014

7. Patz A, Hoeck L, et al. Studies on the effect of high oxygen administration in retrolental fibroplasia. Nursery observations. Am J Ophthalmol. 35:1248, 1952.

8. Avery ME, Oppenheimer EH. Recent increase in mortality from hyaline membrane disease. J Pediatr. 57:553,1960.

9. Win Tin. Oxygen Therapy: 50 Years of Uncertainty. PEDIATRICS Vol. 110 No. 3 September 2002, pp. 615-616

0. Shweki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;358:843-5.

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.

2. Fruttiger M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmol Vis Sci 2002;43:522-527.

3. Pierce EA, Avery RL, Foley ED, et al. Vascular Endothelial growth factor /vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995;92:905-909.

4. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114(10):1219-28.

5. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001;98(10):5804-8.

6. Prenner JL, Capone A Jr, Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology. 2004 Dec;111(12):2271-3.

7. Aiello L. P., et al. Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. N Engl J Med 1994; 331:1480-1487, Dec 1, 1994.

8. Gragoudas E. S. et al. Pegaptanib for Neovascular Age-Related Macular Degeneration.
N Engl J Med 2004; 351:2805-2816, Dec 30, 2004.

9. McLeod DS, Taomoto M, Cao J, et al. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 2002; 43:474-482.